FREMONT, California, January 3 /PRNewswire/ --

- USB Drives Have Capacity to Hold Over 16 Full-Length High-Definition Movies or an Entire Season of a TV Series

Corsair(R) http://www.corsair.com, a worldwide leader in high performance computer and flash memory products, announced today that it is expanding its Flash Voyager and Flash Survivor USB family lines with new 32GB capacity offerings. The new Corsair 32GB Flash Voyager and Flash Survivor USB drives will be debuted at the Consumer Electronics Show 2008 (CES) next week in Las Vegas in the Corsair Suite at the Wynn Hotel and at Showstoppers CES 2008.

Ultimate Solution for Storing, Transporting & Backing-up Critical Data

BOSTON and CAMBRIDGE, England, January 3 /PRNewswire/ --

- ZigBee technology connects people with their homes via the Internet and mobile phones

AlertMe.com, provider of people-friendly home security, has teamed up with Ember to make it easy for people, wherever they may be, to keep a close eye on their homes by combining ZigBee wireless technology, the Internet and mobile phone networks.

LONDON, January 3 /PRNewswire/ --

- Higher Paycheques, Flexible Work Arrangements, Candidate Screening Online Among Major Trends for 2008 -

CareerBuilder.co.uk, a leading job site in the UK, released the results of its annual job forecast, conducted by Harris Interactive(R), tracking projected hiring and job search activities for the upcoming quarter and 2008. The survey, titled "2008 UK Job Forecast" was conducted between November 14 and December 3, 2007 and included 281 hiring managers and human resource professionals and 507 workers.

CALGARY, Canada, January 3 /PRNewswire/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R).

LYON, France, January 3 /PRNewswire/ --

- Exclusive Agreement for Rabies Monoclonal Antibodies to Fight Fatal Disease

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive collaboration and commercialization agreement with Crucell N.V. (Euronext, NASDAQ: CRXL) for Crucell's rabies monoclonal antibodies (MAbs), next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.